Pacira BioSciences to Participate in Fireside Chats at Three Upcoming Healthcare Conferences
Pacira BioSciences (Nasdaq:PCRX) will join analyst-led fireside chats at three major healthcare conferences in May and June 2026: RBC Capital Markets, Jefferies, and Goldman Sachs.
Rhea-AI Summary
Pacira BioSciences (Nasdaq:PCRX) will join analyst-led fireside chats at three major healthcare conferences in May and June 2026: RBC Capital Markets, Jefferies, and Goldman Sachs. Live audio webcasts and two-week replays will be available on the company’s investor website under the Events section.
Positive
- None.
Negative
- None.
Details
News Market Reaction – PCRX
In the May 13 session, PCRX gained 0.88%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
- RBC conference time
- 8:30AM ET
- 2026 RBC Capital Markets Global Healthcare Conference on May 20, 2026
- Jefferies conference time
- 9:55AM ET
- 2026 Jefferies Global Healthcare Conference on June 3, 2026
- Goldman Sachs conference time
- 1:20PM ET
- Goldman Sachs 47th Annual Global Healthcare Conference 2026 on June 8, 2026
- Conference count
- 3 conferences
- Number of upcoming healthcare conferences with fireside chats
- Replay window
- two weeks
- Duration webcast replay will be available after events
Historical Context
-
Equity awards granted to new employees under inducement plan.
-
Company mailed communication directly to stockholders ahead of meeting.
-
Revenue growth, guidance reiteration, buybacks and pipeline progress reported.
-
Definitive proxy filing highlighting strategy, stock performance and repurchases.
-
Study showed lower opioid use and medical costs with EXPAREL in hip surgery.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BRISBANE, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that it will participate in analyst-led fireside chats at the following three healthcare conferences:
- 2026 RBC Capital Markets Global Healthcare Conference on Wednesday, May 20th at 8:30AM ET.
- 2026 Jefferies Global Healthcare Conference on Wednesday, June 3rd at 9:55AM ET.
- Goldman Sachs 47th Annual Global Healthcare Conference 2026 on Monday, June 8th at 1:20PM ET.
Live audio of the events can be accessed by visiting the “Events” page of the company’s website at investor.pacira.com. A replay of the webcast will also be available for two weeks following the event.
About Pacira
Pacira delivers innovative, non-opioid pain therapies to transform the lives of patients. Pacira has three commercial-stage non-opioid treatments: EXPAREL® (bupivacaine liposome injectable suspension), a long-acting local analgesic currently approved for infiltration, fascial plane block, and as an interscalene brachial plexus nerve block, an adductor canal nerve block, and a sciatic nerve block in the popliteal fossa for postsurgical pain management; ZILRETTA® (triamcinolone acetonide extended-release injectable suspension), an extended-release, intra-articular injection indicated for the management of osteoarthritis knee pain; and iovera®º, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. The company is also advancing a pipeline of clinical-stage assets for musculoskeletal pain and adjacencies, its most advanced product candidate, PCRX-201 (enekinragene inzadenovec), a novel locally administered gene therapy in Phase 2 clinical development for osteoarthritis of the knee. To learn more about Pacira, visit www.pacira.com.
Company Contact: Pacira BioSciences, Inc. Christian Pedetti (973) 254-4387 Christian.pedetti@pacira.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.